HCN Oncology Year-in-Review: Breast CancerDecember 21, 2021 | Oncology Internal Medicine Effect of Celecoxib vs. Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients with Breast Cancer Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. placebo among 2,639 patients recruited between 2007 and 2012, with follow-up 10 years after treatment completion. Read full article Internal Medicine FDA Grants Fast Track Status to Cosela for Triple-Negative Breast Cancer (TNBC) Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced or metastatic TNBC. Read full article Cardiology Association of Breast Cancer Irradiation With Cardiac Toxic Effects In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially high CV disease risk has increased. Read full article Internal Medicine Assessment of 25-Year Survival of Women with ER+/ERBB2- Breast Cancer Treated w. and without Tamoxifen Therapy This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated in the Stockholm tamoxifen (STO-3) trial from 1976 to 1990. Read full article Internal Medicine Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-Risk Breast Cancer Publication: JAMA Oncology Design: An analysis of data from the I-SPY2 randomized clinical trial that included 938 women with breast cancer.Results: In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of cancer subtype and treatment. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS